IL17A and inflammatory bowel disease: In contrast, interleukin-23 inhibitors (such as Ustekinumab) selectively reduce IL-17 produced through the IL-23-dependent pathway, thereby alleviating inflammation and achieving remission in IBD, while IL-23-independent IL-17 remains capable of maintaining epithelial barrier integrity and preserving microbial balance (47).